Semantic Coherence: Kamada Pharmaceuticals – Signal Evidence & AI Readability

EACH LIFE IS UNIQUE

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.
READ MORE

[IMG: Watch the video]

[H2] Latest Updates

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
May. 13, 2026

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
May. 6, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Mar. 31, 2026

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Mar. 26, 2026

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
Mar. 11, 2026

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
Mar. 11, 2026

[IMG: Kamada to Present at WTC Transplant Summit 2025:]

[H2] UPCOMING EVENT
Kamada to Present at WTC Transplant Summit 2025:
Aug. 2 - 6, 2025San Francisco, CA USA

[IMG: Company Presentation]

[H2] UPDATED COMPANY PRESENTATION

[H2] PRODUCTS
Our proprietary platform technology and know-how allow us to extract and purify protein therapeutics from human plasma.
OURPRODUCTS

[H2] PIPELINE
Kamada’s Inhaled AAT has the potential of becoming a transformational next- generation augmentation therapy for Alpha-1 Antitrypsin Deficiency patients.
View Pipeline

[H2] ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION

[IMG: Watch the video]
The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions.
This video illustrates the mechanism of action of AAT, and its possible therapeutic effects.

[H3] Committed to Alpha-1 Patients

Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
Read more

[H3] Supporting prevention of CMV disease after solid organ transplantation

Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans.
Read more

[H3] MORETHERAPEUTICFOCUSAREAS

Science

[H1] Therapeutic Focus Areas

[IMG: Alpha-1 Antitrypsin Deficiency]

[H2] Alpha-1 Antitrypsin Deficiency
Committed to Alpha-1 Patients
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
READ MORE

[IMG: CMV Disease]

[H2] CMV Disease
Supporting prevention of CMV disease after solid organ transplantation
Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans.
READ MORE

[IMG: COVID-19]

[H2] COVID-19
Taking part in the fight against COVID-19
Over the past months, our lives have changed dramatically as a result of the Coronavirus (COVID-19) pandemic. COVID-19 is caused by the novel virus SARS-CoV-2. As new facts about the virus and the pandemic are revealed, the international scientific community, along with the pharmaceutical industry, are making tremendous efforts in order to combat the disease. […]
READ MORE

[IMG: Hepatitis B recurrence after liver transplantation]

[H2] Hepatitis B recurrence after liver transplantation

Hepatitis B is a liver infection caused by the hepatitis B virus. It is a major global health problem. Some people with hepatitis B are sick for only a few weeks (known as an “acute” infection). Some people, especially those who get infected in adulthood, can clear the virus from their bodies without treatment. Hepatitis […]
READ MORE

[IMG: Rabies]

[H2] Rabies
Helping to prevent one of the deadliest diseases in the world
Rabies is a preventable infectious viral disease that is almost always fatal following the onset of clinical symptoms. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild animals. It is spread to people through bites or scratches, usually via saliva. […]
READ MORE

About

[H1] Company Profile & Milestones

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

The company’s strategy is focused on driving profitable growth from current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S.

Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia.

Investors & Media

[H1] News

13 May. 2026

[H3] Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company’s Products Continues to Increase, Supporting the Company’s Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 […]

6 May. 2026

[H3] Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
REHOVOT, Israel, and HOBOKEN, NJ – May 6, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the first quarter ended March […]

31 Mar. 2026

[H3] Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
REHOVOT, Israel, and HOBOKEN, NJ – March 31, 2026 – Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the […]

26 Mar. 2026

[H3] Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity The Center is Structured to Collect Normal Source Plasma and Specialty Plasma, […]

11 Mar. 2026

[H3] Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
REHOVOT, Israel, and HOBOKEN, NJ – March 11, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately […]

11 Mar. 2026

[H3] Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic Growth Generated $25.5 Million […]

4 Mar. 2026

[H3] Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
REHOVOT, Israel, and HOBOKEN, NJ – March 4, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year […]

7 Jan. 2026

[H3] Kamada Provides 2026 Annual Guidance of $200 – $205 Million in Revenues and $50 – $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million […]

18 Dec. 2025

[H3] Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived Products Supply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28 Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Kamada Projects Double-Digit […]

8 Dec. 2025

[H3] Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA Kamada Reiterates its 2025 Full-Year Revenue Guidance […]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27